Division of Cardiology, "Tor Vergata" University Hospital, v.le Oxford 81, Rome 00133, Italy.
Division of Cardiology, "Tor Vergata" University Hospital, v.le Oxford 81, Rome 00133, Italy; Department of Biomedicine and Prevention, "Tor Vergata" University of Rome, Rome 00133, Italy.
Card Electrophysiol Clin. 2022 Mar;14(1):41-52. doi: 10.1016/j.ccep.2021.10.005. Epub 2021 Oct 30.
COVID-19 is an acute respiratory disease of viral origin caused by SARS-CoV-2. This disease is associated with a hypercoagulable state resulting in arterial and venous thrombotic events. The latter are more frequent, especially in patients who develop a severe form of the disease and are associated with an increased mortality rate. It is therefore essential to identify patients at higher risk to initiate antithrombotic therapy. Hospitalized patients treated with treatment dose of anticoagulants had better outcomes than those treated with prophylactic dose. However, several trials are ongoing to better define the therapeutic and prevention strategies for this insidious complication.
新型冠状病毒肺炎（COVID-19）是一种由严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的急性呼吸道传染病。这种疾病与一种高凝状态有关，导致动脉和静脉血栓栓塞事件。后者更为常见，尤其是在发生严重疾病的患者中，且与死亡率增加有关。因此，识别出处于高风险的患者并启动抗血栓治疗至关重要。与接受预防性剂量抗凝治疗的住院患者相比，接受治疗剂量抗凝治疗的患者结局更好。然而，目前正在进行多项试验，以更好地确定这种隐匿性并发症的治疗和预防策略。
